The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Funding Opportunities

EGFR Resisters/LUNGevity issues RFA for FY21 award program in EGFR-positive lung cancer research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

EGFR Resisters and LUNGevity Foundation have issued a Request for Application for the EGFR-Positive lung cancer research program.

Funded research is expected to include at least one aim that is translational and must be directly related to improvement in patient outcomes and/or lead to a clinical trial. The EGFR-Positive award is open to researchers at U.S. and international institutions. At the time of application, an international candidate must name a co-principal investigator who is employed at a U.S. institution. A successful applicant may receive up to $200,000 over an award term of two years.

The Request for Applications will be posted as of June 18 on the LUNGevity website and on the proposalCENTRAL website. For more information, contact Margery Jacobson at mjacobson@LUNGevity.org or 312-407-6109.

Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out. 
By Jacquelyn Cobb
Cancer History ProjectEditorial

Calabresi’s “Cancer at a Crossroads” report was the first step toward historic doubling of the NIH budget
Fox Chase’s Winn contemplates Crossroads 2.0

At a lecture at Yale Cancer Center recently, Robert A. Winn brandished a copy of a 32-year old booklet titled “Cancer at a Crossroads: A Report to Congress for the Nation,” using it as a show-and-tell prop in arguing that America’s cancer program is once again at a crossroads and therefore in urgent need of strategic thinking (The Cancer Letter, April 10, 2026).
By Paul Goldberg
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account